Marketing: Page 85
-
AZ faces Texas lawsuit over bribery, improper marketing of antipsychotic drug
The Texas Attorney General claims in a new lawsuit that AstraZeneca marketed Seroquel for unapproved purposes and paid kickbacks to docs and state health officials.
By Sy Mukherjee • Oct. 13, 2014 -
Study: Pricey specialty med costs worth it in the long run
The research gives pharma cover and a powerful talking point on the exorbitant costs of specialty meds.
By Nicole Gray • Oct. 13, 2014 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
UPDATED: On to the next one: FDA approves new Gilead hep C combo pill Harvoni
Harvoni, which combines Sovaldi (sofosbuvir) and ledipasvir, will eliminate the need for interferon and ribavarin and cost $94,500 for 12 weeks of treatment.
By Sy Mukherjee • Oct. 10, 2014 -
Groups urge stronger psych warnings for controversial Pfizer anti-smoking drug
Citing numerous studies, several consumer groups are calling on Pfizer to include stronger warnings about Chantix-related side effects, including thoughts of suicide, aggression, and psychosis.
By Nicole Gray • Oct. 9, 2014 -
Look out, AbbVie: Here comes Amgen's Humira biosimilar
Amgen's ABP501 is emerging as a serious biosimililar contender to Humira (adalimumab), which is slated to go off patent in 2016.
By Nicole Gray • Oct. 9, 2014 -
Is the UK's NHS about to snub Sovaldi?
New UK government data shows that Gilead's pricey hep C cure could cost the NHS more than it's willing to spend.
By Sy Mukherjee • Oct. 8, 2014 -
Teva's downsizing efforts squeeze out women's health and cancer R&D
Between 2015 and 2017, Teva plans to save $550 million by discontinuing 14 pipeline projects.
By Nicole Gray • Oct. 7, 2014 -
Ascension Health bans Genentech sales reps from campus
The ban is in response to Genentech's notice that three top-selling cancer drugs will only be available through six specialty dealers, with no wholesales access for hospitals.
By Nicole Gray • Oct. 6, 2014 -
Breast cancer drug sales to increase almost two-fold by 2023
Treatment sales at large are expected to increase an average of 5.8% per year.
By Nicole Gray • Oct. 3, 2014 -
Salud: NHS to endorse daily pill for heavy drinkers in England
Do you live in England? Drink a lot of alcohol, but not ready for rehab? Then the Selincro, Lundbeck's once-daily pill for heavy drinkers, might be right for you.
By Nicole Gray • Oct. 2, 2014 -
Specialty pharma ready to dispense Xtandi after expanded indication
Diplomat, a specialty pharmacy, is stocking up Xtandi, as the drug is now approved and available for patients with prostate cancer in all stages of disease progression.
By Nicole Gray • Oct. 2, 2014 -
Report: 700-plus biosimilars in development worldwide
Thomson Reuters Bioworld reports that 245 biopharma companies are at work on biosimilars -- a market segment with projected sales of $25 billion by 2019.
By Nicole Gray • Sept. 30, 2014 -
Deep Dive
Access wanted: What it takes for patients to get the drugs they need
The U.S. ranks 7th in terms of patient access to drugs, right alongside Central and South America -- and different patient groups face their own unique barriers to access.
By Nicole Gray • Sept. 30, 2014 -
Acquisition update: Daiichi Sankyo buys Ambit Biosciences for $410 million
Daiichi is shoring up its oncology portfolio as it acquires Ambit’s late-stage acute myeloid leukemia drug, along with other cancer treatments.
By Nicole Gray • Sept. 30, 2014 -
Actavis to continue sales of cheaper Alzheimer's drug for 60 days
The response to Actavis' "forced switch" from Namenda (memantine) IR to the new Namenda XR formulation has been contentious -- and litigious.
By Nicole Gray • Sept. 26, 2014 -
BI to cut up to 600 jobs in Germany
Grappling with a lackluster sales year, Boehringher Ingelheim (BI) is looking to slash costs by $572 million by the end of 2016.
By Nicole Gray • Sept. 25, 2014 -
Deep Dive
Collaborating with Chinese pharma: Inside one company's success story
CleveXel CEO Christian Bloy tells BioPharma Dive how his company cultivated collaborative relationships and leveraged its expertise in development and innovation to develop anti-malarials in China.
By Nicole Gray • Sept. 23, 2014 -
UK public health advocates: Boys need HPV vaccine, too
US, Australia, Austria and parts of Canada already make the vaccine available for boys. Will the UK join them?
By Nicole Gray • Sept. 23, 2014 -
Bayer to spin off material science division into separate company
Bayer says goodbye to its three-pillar business model as healthcare takes center stage.
By Nicole Gray • Sept. 19, 2014 -
Instant pleasure: Vivus ED pill wins faster-acting 'on demand' label
FDA blessing in hand, Auxilium can now market Vivus' Stendra as being effective for use a mere 15 minutes before sex.
By Sy Mukherjee • Sept. 18, 2014 -
UPDATED: Report: Sovaldi dropout rate 4 times higher than in trials
A CVS Health Corp analysis finds a "plateau and downward trend" in use of Gilead's $1,000-per-pill Hep C cure.
By Sy Mukherjee • Sept. 17, 2014 -
Roche's cheaper vision loss drug just as effective as Novartis' Lucentis
Novartis’ Lucentis and Roche’s Avastin are similarly effective against wet age-related macular degeneration. But only one is approved for treating the condition -- even though the other is far cheaper.
By Nicole Gray • Sept. 16, 2014 -
Gilead to allow Indian generics of pricey Sovaldi in developing nations
The deal covers 91 countries that contain more than half of the global infected population.
By Sy Mukherjee • Sept. 15, 2014 -
Report: Psoriatic arthritis market to cross $3.7 billion by 2023
Decision Resources analysts anticipate a 66% increase in psoriatic arthritis' market value over the next 10 years, largely thanks to biologics.
By Nicole Gray • Sept. 12, 2014 -
Deep Dive
New statin guidelines: Thoughts from a physician on the front lines
“It seems that just about everyone over the age of 65 needs to be on a statin based on the new guidelines,” says Dr. Barry Mennen.
By Nicole Gray • Sept. 11, 2014
Previous
